TSX Venture Exchange: NVC
VANCOUVER, Feb. 22, 2012 /CNW/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular
disease, today announced that the company will participate in the
Lazard Capital Markets Annual Medical Technology and Life
Sciences/Tools Snowbird Conference. The event is being held at the
Snowbird Resort in Snowbird, UT February 29-March 2, 2012.
The conference format consists of one-on-one meetings between
participating companies and institutional investors. Investors
interested in meeting with Neovasc should contact Lazard Capital
About Neovasc Inc.
Neovasc Inc. is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Neovasc Reducer™
for the treatment of refractory angina, the Tiara™ technology in
development for the transcatheter treatment of mitral valve disease and
a line of advanced biological tissue products that are used as key
components in a variety of third-party medical products, such as
vascular surgical patches and transcatheter heart valves. For more
information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
For further information:
U.S. media & investor contact:
GendeLLindheim BioCom Partners
212 584-2276, ext. 201